AndrewH.KoMD

Oncology • San Francisco, CA

Professor of Medicine and Associate Chief, UCSF

Join to view full profile

Dr. Ko is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ko's full profile

Already have an account?

Office
1825 4th St
San Francisco, CA 94143
Phone+1 415-353-9888

Fax+1 415-353-9931

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1998 - 2000
Beth Israel Hospital, Harvard Medical SchoolInternal Medicine, 1995 - 1998
Johns Hopkins University School of MedicineClass of 1995

Certifications & Licensure

CA State Medical License 1998 - 2026
American Board of Internal Medicine Medical Oncology

Clinical Trials

Gemcitabine, Cisplatin, and Bevacizumab in Treating Patients With Metastatic Pancreatic Cancer Start of enrollment: 2004 Apr 01
Completed
Phase 2
Gefitinib, Cisplatin, Irinotecan, and Radiation Therapy Before Surgery in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery Start of enrollment: 2005 Nov 01
Terminated
Phase 1
Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine Start of enrollment: 2006 Feb 01
Completed
Phase 2
Gemcitabine and Bevacizumab in Treating Patients With Pancreatic Cancer That Has Been Completely Removed By Surgery Start of enrollment: 2006 Jul 01
Terminated
Phase 1, Phase 2
Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer Start of enrollment: 2007 Jan 22
Terminated
Phase 2
Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers Start of enrollment: 2008 Feb 01
Completed
Phase 1
Study of PEP02 as a Second Line Therapy for Metastatic Pancreatic Cancer Start of enrollment: 2009 Jan 01
Completed
Phase 2
A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer Start of enrollment: 2010 May 01
Terminated
Phase 1
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma Start of enrollment: 2011 Aug 23
Completed
Phase 1
Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma Start of enrollment: 2012 Oct 05
Completed
Phase 2
Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma Start of enrollment: 2013 Apr 01
Completed
Phase 1
Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting Start of enrollment: 2014 Feb 05
Completed
Phase 2
PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma Start of enrollment: 2015 Jul 14
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

715 citations
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
Ronan J. Kelly, Jaffer A. Ajani, Jarosław Kużdżał, Thomas Zander, Eric Van Cutsem
The New England Journal of Medicine. 2021-04-01
725 citations
Pancreatic adenocarcinoma, version 2.2017: Clinical practice guidelines in Oncology
Margaret A. Tempero, Mokenge P. Malafa, Mahmoud M. Al-Hawary, Horacio J. Asbun, Andrew Bain
Journal of the National Comprehensive Cancer Network. 2017-08-01
163 citations
A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma
Andrew H. Ko, Noelle K. LoConte, Margaret A. Tempero, Evan J. Walker, R. Kate Kelley
Pancreas. 2016-03-01

Lectures

Phase Ia, first-in-human study of AbGn-107, a novel antibody-drug conjugate (ADC), in patients with gastric, colorectal, pancreatic, or biliary cancers.
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
Continuing Medical Education (CME) Comprehensive Oncology Review
Continuing Medical Education Institute, Inc, Seattle, Washington - 9/22/2012

Press Mentions

Navigating Life During and After Cancer as a Young Adult: A Patient PerspectiveNovember 29th, 2022
Apexigen Presents New Data from a Phase 2 Trial Evaluating Its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022September 10th, 2022
Reading the Scientific Study to Understand a Pancreatic Cancer TreatmentJune 3rd, 2019
Join now to see all

AndrewH.KoMD

Dr. Ko is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.